Tuvusertib Drug Asset Due Diligence Report 2026

This Tuvusertib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Tuvusertib can convert its Small molecule drug profile and ATR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tuvusertib (query alias: tuvusertib)
Modality / target	Small molecule drug; ATR; ATR inhibitors
Highest global status	Phase 2
Originator	EMD Serono, Inc.
Active developers	Merck KGaA, National Cancer Institute, EMD Serono Research & Development Institute, Inc.

The MCP disease footprint includes Astrocytoma, IDH-Mutant, Recurrent Endometrial Cancer, HRD-positive Ovarian Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06433219	Phase 2	Active, not recruiting	63	Part A and Part B: Confirmed Objective Response (OR) According to RECIST v1.1 as Assessed by Investigator
NCT07417761	Phase 2	Recruiting	56	6-months progression-free survival (PFS) rate
NCT06518564	Phase 2	Recruiting	25	Progression Free Survival at 6 months (PFS6)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

MATRiX: A randomized phase II trial of tuvusertib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma.

Phase 2; n=34; evaluation: Positive. Reported fields: ORR = 20.8 % ( 7.1 - 42.2); -

599 The MATRiX trial: a multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1-refractory merkel cell carcinoma | Journal for ImmunoTherapy of Cancer

Phase 2; n=24; evaluation: Positive. Reported fields: PD = 100.0 % ; PD = 100.0 %

618TiP - Phase I/II study of tuvusertib, an ATR inhibitor in combinaison with fulvestrant in hormone receptor-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitors plus aromatase inhibitor-based endocrine treatments and in various molecular contexts (MATRIx)

Phase 1/2; n=45; evaluation: Positive. Reported fields: AE = The most common treatment-related AEs were low white blood cell count (30%, grade 1/2) and loss of appetite (13%, grade 1 only). ; AE = The most common treatment-related AEs were low white blood cell count (30%, grade 1/2) and loss of appetite (13%, grade 1 only). ; AE = The most common treatment-related AEs were low white blood cell count (30%, grade 1/2) and loss of appetite (13%, grade 1 only).

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tuvusertib addresses Astrocytoma, IDH-Mutant, Recurrent Endometrial Cancer, HRD-positive Ovarian Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 10 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: ATR records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-04-14	CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates	Preclinical	US$300.0M stated total
2025-11-17	Repare finds fix as biotech agrees to XenoTherapeutics buyout	Phase 1	US$94.8M stated total
2025-05-30	爱科百发与Partex深化战略合作，共同推进新型ATR抑制剂AK0658的全球开发	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Inhibitors of ataxia-telangiectasia mutated and RAD3-related protein kinase (ATR) for use in methods of treating cancer”. The milestone feed surfaced a patent-application signal described as “Compounds useful as inhibitors of ATR kinase”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO